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REGULAR ARTICLE
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Key Points
• Low variant allele fre-
quency clonal hemato-
poiesis or aberrant
CD7 expression on he-
matopoietic stem cells
increases the risk
of tMN.
• Patients at high risk of
developing tMN after
ASCT can be identified
at the time of
leukapheresis.
Therapy-relatedmyeloid neoplasms (tMN) develop after exposure to cytotoxic and radiation
therapy, and due to their adverse prognosis, it is of paramount interest to identify patients at
high risk. The presence of clonal hematopoiesis has been shown to increase the risk of
developing tMN. The value of analyzing hematopoietic stem cells harvested at leukapheresis
before autologous stem cell transplantation (ASCT) with next-generation sequencing and
immunophenotyping represents potentially informative parameters that have yet to be
discovered. We performed a nested case-control study to elucidate the association between
clonal hematopoiesis, mobilization potential, and aberrant immunophenotype in
leukapheresis products with the development of tMN after ASCT. A total of 36 patients with
nonmyeloid disease whowere diagnosedwith tMN after treatment with ASCTwere included
as case subjects. Case subjects were identified from a cohort of 1130 patients treated with
ASCT and matched with 36 control subjects who did not develop tMN after ASCT. Case
subjects were significantly poorer mobilizers of CD341 cells at leukapheresis (P 5 .016),
indicating that these patients possess inferior bone marrow function. Both clonal
hematopoiesis (odds ratio, 5.9; 95% confidence interval, 1.8-19.1; P 5 .003) and aberrant
expression of CD7 (odds ratio, 6.6; 95% confidence interval, 1.6-26.2; P 5 .004) at the time of
ASCT were associated with an increased risk of developing tMN after ASCT. In conclusion,
clonal hematopoiesis, present at low variant allele frequencies, and aberrant CD7
expression on stem cells in leukapheresis products from patients with nonmyeloid
hematologic cancer hold potential for the early identification of patients at high risk of
developing tMN after ASCT.
Introduction
Therapy-related myeloid neoplasms (tMN) are high-risk neoplasms evolving after exposure to a number
of antineoplastic agents, including alkylating agents, topoisomerase inhibitors, and radiotherapy; they include
therapy-related myeloproliferative neoplasms (tMPN), myelodysplastic syndrome (tMDS), and acute myeloid
leukemia (tAML).1 As such, cytoreduction as part of autologous stem cell transplantation (ASCT) increases
the risk of developing tMN.2,3 Given the increasing use of ASCT, better supportive care, and new and more
potent antineoplastic drugs available for several lines of therapy, the incidence of tMN is expected to further
increase in the future.4 As reflected in the high frequency of adverse cytogenetic andmutational profiles in this
subset of patients, it is well established that patients diagnosed with tMN experience a dismal prognosis.5-9
Submitted 28 October 2019; accepted 15 January 2020; published online 9 March
2020. DOI 10.1182/bloodadvances.2019001157.
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Clonal hematopoiesis of indeterminate potential (CHIP) constitutes
a premalignant condition that is characterized by somatic mutations
with a variant allele frequency (VAF) $0.02 in genes related to
hematologic malignancies in patients with absence of cytopenia.
However, no meaningful biological argument for a VAF limit of 0.02
has ever been proposed.10 The term clonal hematopoiesis (CH)
more widely describes detectable somatic mutations at any VAF
and thus contains the entire spectrum of premalignant conditions
related to somatic mutations in genes associated with myeloid
disorders. CH has been shown to increase all-cause mortality,
atherosclerosis, and the risk of developing de novo hematologic
neoplasms, as well as tMN.11-16 Moreover, in patients with CH, high-
dose conditioning regimens as part of treatment with ASCT have been
shown to provide a proliferative advantage for mutated cell clones.17
The impact of individual mutations in malignant transformation is still
being investigated. However, it has become evident that mutations in
both DNMT3A and TET2 can be detected in a large fraction of the
healthy adult population18; individually, these clones often display
little to no clonal evolution over time and are associated with a lower
increase in risk of developing myeloid neoplasms compared with
mutations in TP53, IDH1/2, and spliceosome genes.19-22
The prevalence of CH increases with age, with an estimated 10% of
the general population expected to exhibit CH by 70 years of
age.23-25 Of note, CH has been shown to originate in the
hematopoietic stem cell or in a common progenitor.26 In myeloid
malignancies, accumulating evidence suggests that the neoplastic
cell population is maintained by rare and distinct subsets of cells
with stem cell features, so-called leukemic stem cells (LSCs).
Identification of LSCs is primarily based on immunophenotyping by
using flow cytometry (FCM). A number of cell surface markers have
been shown to be aberrantly expressed on the CD341CD38– stem
cells and progenitor cells in AML.27-29 Several markers have been
proposed as useful in the effort to identify putative LSCs, including
the C-type lectin domain family 12 member A receptor (CLEC12A),
CD7, CD19, and CD123, all of which have been shown to be
aberrantly expressed in the CD341CD38– subset in patients with
AML.27-32 The presence of either CH or putative LSCs may drive
initiation of tMN in patients who have been intensively treated for
a nonmyeloid hematologic neoplasm, with the intent to either cure
or achieve a long-lasting remission.
Thus, in the current study, we investigated the presence of CH and
LSCs in patients’ leukapheresis products before ASCT, as well as
their potential to predict development of tMN.We hypothesized that
patients with nonmyeloid primary hematologic neoplasms under-
going ASCT, who developed tMN, had detectable low VAF CH at
time of leukapheresis, and that these mutations represented a risk
factor for the development of tMN. We further investigated if minute
fractions of LSCs were present in leukapheresis products and
whether their identification could be a useful predictor of
developing tMN.
Materials and methods
Patients
The cohort of this nested case-control study consists of patients
treated with ASCT at the Department of Hematology, Aarhus
University Hospital (Aarhus, Denmark), between 1989 and 2016.
Cases were identified via the Danish Pathology Registry, and only
patients without any signs of myeloid disease, clinically or in the
bone marrow biopsy results before ASCT, were included. All tMN
diagnoses were carefully reviewed and verified by an experienced
pathologist. Case subjects were patients with nonmyeloid primary
disease, diagnosed with tMN after ASCT (minimum latency being
90 days). Control subjects were patients with nonmyeloid primary
disease who did not develop tMN after ASCT. Matching 1:1 was
performed on the following variables listed in order of priority: (1)
follow-up time (defined as time elapsed between ASCT and tMN
diagnosis for cases); (2) age (65 years); (3) sex; and (4) conditioning
regimen. Criteria for inclusion for both case and control subjects
were: (1) age 18 to 75 years; (2) treatment with ASCT at the
Department of Hematology at Aarhus University Hospital; and (3)
availability of biobanked mononuclear cells obtained from leukaphe-
resis before ASCT. Criteria for exclusion were: (1) treatment of tMN
at time of ASCT; (2) myeloid disease as indication for ASCT; and (3)
patients who opposed the experimental use of stored tissue as
registered in the national “Tissue Application Register.” A total of 36
cases were included in the study (Figure 1).
The study was approved by the Central Denmark Region
Committees on Health Research Ethics (record no. 1-10-72-396-
17) and the Danish Data Protection Agency (record no. 1-16-02-
851-17). The project was conducted in accordance with the
Declaration of Helsinki.
Flow cytometry
Mononuclear cells harvested as part of leukapheresis before ASCT
were stored in liquid nitrogen in a dimethyl sulfoxide solution. The
cryopreservedmononuclear cells were thawed in 37°Cwater bath and
resuspended in a thawing buffer containing 10% heat-inactivated
1130 patients treated with 
ASCT since 1989. 
1090 patients available for
inclusion. 
38 patients evaluated for tMN.
36 patients diagnosed
with tMN included. 
1 could not be validated by
pathologist.
1 patient did not have available
leukapheresis product.  
40 patients transplanted on
myeloid indication.
1052 patients did not develop
tMN.* 
Figure 1. Flowchart describing inclusion of tMN patients in the case cohort.
The cohort consisted of patients treated with ASCT at the Department of
Hematology, Aarhus University Hospital, from 1989 to 2016. *Control subjects
selected from this group.
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fetal calf serum (Biochrom, Berlin, Germany). Cells were stained
with the following pretitrated monoclonal antibodies: CD123 FITC
(clone AC145; Miltenyi, Bergisch Gladbach, Germany), CLEC12A
PE (clone HB3; Department of Hematology, Aarhus University
Hospital), CD14 ECD (clone RMO52; Beckman Coulter, Brea,
CA), CD34 PerCP-Cy5.5 (clone 581; BioLegend, San Diego, CA),
CD117 PE-Cy7 (clone 104D2; BD Biosciences, Franklin Lakes, NJ),
CD7 APC (clone 124-1D1; Thermo Fisher Scientific, Waltham, MA),
CD19 APC-A700 (clone J3-119; Beckman Coulter), CD38 APC-H7
(clone HB7; BD Biosciences), HLA-DR PB (clone L243; BioLegend),
and CD45 KrO (cloneJ.33; Beckman Coulter). Data were acquired
on a Navios flow cytometer (Beckman Coulter [10 colors; 405, 488,
and 638 nm laser; 51312 photomultiplier tube configuration])
using the Navios Tetra acquisition software. Compensation was set
by using UltraComp eBeads (Thermo Fisher Scientific). Data were
analyzed by using Kaluza Analysis software, version 1.3 (Beckman
Coulter) and illustrated by using FlowJo Data Analysis software,
version 10.6.1 (BD Biosciences).
Analysis was performed independently by 2 experienced inves-
tigators, and both were blinded to case/control status. The gating
strategy is described in detail in supplemental Figure 1. Erythroid
cells (CD45neg/SSClow) and lymphocytes (CD45high/SSClow) were
used as the internal negative/positive gating control for aberrant
antigen expression. A median number of 118 CD341CD38– cells
(range, 6-1281) were analyzed. The difference in absolute numbers
of CD341CD38– cells did not reach statistical significance. A
minimum of 5 clustered cells was regarded as a positive lower limit
in the statistical analysis.
Targeted deep sequencing
Samples were subjected to targeted next-generation sequencing
(NGS) using the commercially available Myeloid Tumor Solution
targeted panel (SOPHiA Genetics, Saint Sulpice, Switzerland).
NGS was performed in accordance with the manufacturer’s
instructions and subsequently analyzed in SOPHiA DDM analysis
software (SOPHiA Genetics). The panel covers 30 genes re-
currently mutated in myeloid neoplasms: ABL, ASXL1, BRAF,
CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3,
HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS,
PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1,
WT1, and ZRSR2. Cutoffs for VAF and read depth for the variant
calling algorithm was determined by analysis of variant call format
(.vcf) files from all patients (supplemental Figure 2). Variants were
excluded if: (1) read depth was,3000 reads; (2) VAF was,0.003;
(3) variant location was outside of 625 nucleotides of coding
regions; (4) variant was an indel present in a homopolymeric
stretch; and (5) variant was suspected germline with VAF over 0.95,
or between 0.45 and 0.55, and reported in the Exome Aggregation
Consortium database.33 Mutations in DNMT3A and TET2 were
excluded from the statistical analysis because they have been
frequently reported as benign age-related changes in the hemato-
poietic stem cells; they are shown to be frequently present in the
healthy population and reportedly confer a low risk of malignant
transformation.18,19,21,34 Data from the NGS analysis were in-
dependently evaluated by 2 investigators.
Statistical analyses
Continuous variables were compared by using the Wilcoxon rank
sum nonparametric test. Categorical variables were analyzed by
using the Pearson x2 test. All estimates were reported with a 95%
confidence interval (CI), and P , .05 was considered significant.
Stata version 15.1 (StataCorp LLC, TX) was used for statistical
analyses.
Results
Study cohort
The cohort consisted of 36 tMN patients and 36 control subjects.
Of the 36 cases, 10 patients were diagnosed with tAML, 25 with
tMDS, and 1 with unclassifiable tMPN. In total, 7 (19.4%) of 36
patients were female, and the median age at ASCT was 55 years
(range, 29-69 years) for patients and 56 years (range, 35-67 years)
for control subjects (Table 1). All patients received an alkylating
agent, a topoisomerase II inhibitor, or both as part of their
conditioning regimen. No difference was observed in the proportion
of patients treated with cytotoxic maintenance therapy post-ASCT
between the groups (supplemental Table 1A-B). Median time from
ASCT to diagnosis of tMN was 3.5 years (range, 0.2-18.1 years),
and patients with tMDS and tAML presented with similar clinical
characteristics at diagnosis (supplemental Table 2).
Stem cell mobilization at leukapheresis
As part of the leukapheresis, all patients were stimulated with
granulocyte colony-stimulating factor and a priming regimen
(supplemental Table 1A-B). Case subjects mobilized significantly
fewer CD341 stem cells than control subjects (Table 1), with
a median of 3.57 3 106 cells/kg (range, 0.4-29 3 106 cells/kg)
compared with 5.32 3 106 cells/kg (range, 2-18 3 106 cells/kg;
P 5 .016), indicating that the normal hematopoiesis could be
impaired as early as at time of ASCT. No differences were found in
regeneration time of neutrophilic granulocytes or platelets, or in the
time of admission.
Clonal hematopoiesis at ASCT and risk of tMN
Targeted NGS of case and control subjects was performed to
reveal the presence of CH (supplemental Table 3). Low VAF
mutations in DNMT3A and TET2 were detected at an equal rate in
both case subjects (50% DNMT3A, 16% TET2) and control
subjects (33% DNMT3A, 28% TET2), and they did not correlate to
an increased risk of developing tMN (P 5 .216) (supplemental
Table 4). After exclusion of DNMT3A and TET2 from the statistical
analysis, the most frequently mutated genes in patients with tMN
were TP53 (26%), ASXL1 (20%), and ZRSR2 (13%) (Figure 2A).
The predicted effects of mutations detected were mainly missense,
with mutations resulting in frameshifts, stop-codons, and splice-
donor mutations being exclusive to case subjects (supplemental
Figure 3A,C). The single nucleotide base shift T.C/G.A was the
most frequently detected and represented 32% (12 of 37) of the
total mutations. Base substitutions, C.T/A.G, G.C and A.C/
G.T, were exclusive to case subjects (supplemental Figure 3B).
Mutations were distributed evenly between age groups, and,
remarkably, all patients harboring mutations at ASCT who were
aged ,50 years developed tMN (Figure 2B). In cases, 47% (95%
CI, 30-64) had one or more mutations at time of ASCT compared
with 14% (95% CI, 4-29) of control subjects. Detectable CH at
time of ASCT was significantly associated with developing tMN,
corresponding to a factor 5.9 increase in risk (OR, 5.9; 95% CI,
1.8-19.1; P 5 .003) (supplemental Table 5). In one patient
(Figure 2C), NGS analysis was also performed at tMN diagnosis.
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This analysis revealed the clonal expansion of a mutation in the
spliceosome gene (SRSF2) from VAF 0.005 at ASCT to VAF 0.45
at tMDS. Of the other mutations detected at ASCT, none persisted
at time of tMN, while other mutations had emerged (data not
shown).
Evaluation of LSCs
Analysis of aberrant marker expression on CD341CD38– stem cells
(Table 1; Figure 3) revealed a significant difference in the presence
of aberrant CD71 stem cells between case and control subjects,
resulting in a factor 6.6 increase in risk of developing tMN after
ASCT (OR, 6.6; 95% CI, 1.6-26.2; P 5 .004) (supplemental
Table 5). Evaluation of aberrant expression of CLEC12A, CD19,
and CD123 on CD341CD38– stem cells revealed no differences
between case and control subjects.
Combining NGS and FCM as a screening method for
development of tMN
Given that both targeted NGS and aberrant expression of CD7 at
the stem cell level are potentially efficacious screening methods to
Table 1. Characteristics of case and control subjects at time of ASCT and results of analysis according to FCM
Variable Case subjects Control subjects P*
Baseline characteristics at ASCT
No. of patients 36 36
Age at ASCT, median (range), y 55.0 (29-69) 56.6 (35-67) .50
Sex, female/male 7/29 7/29
Follow-up, median (range), y 3.5 (0.2-18.1) 8.2 (2.2-16.7) , .001
Cytotoxic treatment post-ASCT, yes/no 0.38 0.50 .393
Read depth of NGS, median (range) 8 606 (4 540-10866) 9 061 (7 027-10016) .350
Admittance, median (range), d 15.1 (11-31) 15.5 (10-29) .680
Reg. neutrophil granulocytes, median (range), d 11.2 (9-28) 10.8 (9-15) .576
Reg. platelets, median (range), d 17.4 (9-70) 15.1 (9-36) .367
CD341 cells, median (range), 3106/kg 3.57 (0.4-29) 5.32 (2-18) .016
FCM
CD341CD38– fraction, median (range), % 0.022 (0.004-0.14) 0.015 (0.0001-0.06) , .001
CD341CD38–CLEC12A1, % (CI 95%), yes/no 3.1 (0.07-16.21) 2.7 (0.07-14.52) .933
CD341CD38–CD71, % (CI 95%), yes/no 37.5 (21.1-56.3) 8.3 (1.7-22.4) .004
CD341CD38–CD191, % (CI 95%), yes/no 0 0
CD341CD38–CD1231, % (CI 95%), yes/no 15.6 (5.2-32.7) 8.3 (1.7-22.4) .352
Reg, regeneration.
*P values for Wilcoxon-Mann-Whitney test and Pearson x2 test.
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Figure 2. Somatic mutations detected pre-ASCT. Results of targeted deep sequencing of case (red) and control subjects (blue). (A) Total number of mutations according
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identify patients at high risk of developing tMN, we analyzed the
performance of combining NGS and FCM as a screening tool. By
using a simple binary outcome screening method, we would have
been able to correctly identify 24 (66%) of 36 case subjects already
at ASCT, whereas 8 (22%) of 36 control subjects would have
been misclassified as cases. This suggests that NGS and FCM
complement each other in a clinical setting, with the 2 methods
combined in a simple algorithm yielding a sensitivity of 66% and
a specificity of 78%. This corresponds to a positive predictive value
of 75% and a negative predictive value of 70%.
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Figure 3. Flow cytometric analysis of aberrant CD7 expression within the stem cell subset. The CD341CD38– stem cells were identified within the CD45lowSSClow
CD14– cells (left panel), and the presence (A) or absence (B) of aberrant CD71 cells were evaluated by using a bivariate plot of SSC-A vs CD7 (middle panel). The right panel
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Discussion
In this nested case-control study of patients developing tMN after
ASCT, we found that the presence of CH before ASCT increases
the risk of developing tMN with a factor of 5.9. The high number of
tMN patients with available biobanked cells from leukapheresis
products allowed for a robust estimate for development of tMN. Our
data are in line with recently published data by Young et al35 who
found a factor 5.4 increase in the risk of developing AML associated
with detectable CH at a VAF of $0.01, as well as the ability to
detect the presence of low VAF mutations several years before
onset of tMN.36,37 To the best of our knowledge, the current study is
the first to show that aberrant CD7 expression on the stem cell
population from leukapheresis products is associated with an
almost sevenfold increase in risk of developing tMN. Furthermore,
we found that patients with tMN were poorer stem cell mobilizers
during leukapheresis compared with control subjects. Collectively,
these findings show that at ASCT, patients with low VAF mutations
associated with myeloid neoplasms, or with aberrant CD7 expression
within the stem cell subset, are at high risk of developing tMN.
Intriguingly, our results suggest that FCM is a highly accurate
method for early identification of patients at risk of developing tMN,
and we have shown that both NGS and FCM are useful methods in
the early identification of patients at high risk of developing tMN.
Importantly, these methods identified different patients in the tMN
cohort, overlapping in just 5 patients, and only 3 control subjects
displayed aberrant CD7 expression, all with a minimum of 10 years
of follow-up (supplemental Table 1). All 5 patients with both
detectable CH and expression of CD7 developed tMN, alluding to
coexpression of CH and CD7 as a potential future predictor of tMN.
However, the data require validation in a larger and independent
cohort and cannot yet be considered for clinical evaluation of risk of
tMN before ASCT. Cell sorting of CD71 stem cells is needed for
molecular and functional studies and is a prerequisite to unravel
their potential role in the pathogenesis of tMN.
Four cases did not have their samples analyzed by FCM due to
sparse sample material, suggesting that the actual predictive
potential of our simple binary outcome screening could be even
higher than reported here.
Immunophenotypic characterization of malignant stem cells has
been studied in patients with AML and MDS, and the fraction of
such aberrant marker–positive cells has been shown to hold
prognostic impact at diagnosis and during treatment.38 Moreover,
antigen targeting is an appealing approach in cancer treatment.29,39
Routinely, leukapheresis products are evaluated by FCM to
enumerate CD341 cells, and simultaneous evaluation of aberrant
CD7 expression on CD381CD34– cells would be feasible in most
laboratories as performed in diagnostic and MRD settings of AML
and MDS, as shown by Zeijlemaker et al.28
Targeted NGS offers the advantage of accurate prediction of
which specific mutations confer an actual risk of tMN, albeit this
perspective will be consolidated in the future. The accumulating
evidence pointing to the increased risk of tMN in patients with CH
who are treated with ASCT makes close monitoring with early
intervention an alluring and feasible option. Third, results could imply
reevaluation of the indication for ASCT for patients with tMN-
associated mutations who were allocated for ASCT for an incurable
neoplasm (eg, patients with multiple myeloma). However, for
a considerable group of patients, the decision to pursue treatment
with ASCT would be unaffected by the presence of CH in the
leukapheresis product. Undoubtedly, future prognostic models and
more accurate prediction tools will guide clinical decision-making.
One patient sequenced at ASCT and at tMN showed that CH,
present at low VAF at ASCT, had the potential to expand toward
tMN. This finding challenges the validity of the VAF 0.02 limit to
qualify for the CHIP diagnosis, especially considering the fact that
we have shown the relevance of mutations with VAFs as low as
0.003. Thus, our findings suggest both a biological and a clinical
impact of low VAF mutations detected by using NGS. To further
scrutinize the pathogenesis of progression from CH to tMN, the
subject of future research should focus on the underlying
mechanisms behind the evolutionary potential and interplay of
individual mutations.
In the current study, we used a commercially available panel limited
to 30 genes, as used in routine diagnostics of MDS and AML at our
institution. Specifically, this panel did not include PPM1D, which in
recent publications has been strongly correlated with tMN.40,41
Notably, in our cohort, case subjects could have had an
undiagnosed myeloid malignancy that was not identified in
histologic analysis of bone marrow biopsy specimens before ASCT,
and the apparent development of tMN could thus represent
progression of an undiagnosed preexisting condition. In particular,
patient 1179 had a classic CALR mutation at a VAF of 0.40,
strongly suggesting that this patient had an undiagnosed myelo-
proliferative neoplasm before treatment with ASCT; hence, it
cannot be excluded that the tMPN diagnosis in fact represents
progression from an undiagnosed myeloproliferative neoplasm.
Furthermore, we did not have available samples to evaluate whether
variants reported could represent potential germline mutations, in
particular mutations present at VAFs of 0.44 to 0.55 and .0.95,
and it is therefore possible that our results could contain rare
germline variants.
Preferentially, data from NGS analyses on tMN samples would
enable evaluation of the clonal evolution of mutations present at
ASCT. Theoretically, the clones detected at ASCT might not
undergo evolution themselves and cause tMN but may act in a more
complex interplay with other molecular aberrations. Also, we expect
that the incidence of tMN in our cohort of ASCT patients, in
particular tMDS, could be underestimated. Mild persistent cytope-
nia, which can be an early sign of tMDS, in patients who have been
treated with ASCT may to some extent be accepted without
performing diagnostic analyses. Furthermore, patients with relapse
of their primary disease could be spared from undergoing new
biopsies, as curative intent could be out of reach. Finally, the
diagnosis of tMDS could have been achieved in other ways, such as
identified according to MDS-specific cytogenetic abnormalities.
In conclusion, we performed a nested case-control study on
patients who developed tMN after ASCT. We found that screening
for mutational status and aberrant expression of CD7 on
hematopoietic stem cells at time of ASCT can identify patients at
high risk of developing tMN. We further established that mutations
were relevant, and predictive, of tMN at VAFs lower than 0.02. New
research into the predictive potential of the individual mutations in
the spectrum of CH, preferably combined with sequential NGS
analyses to map the potential evolution of early leukemic clones
over time, will drive future clinical decision-making.
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